Patents by Inventor Keith Pfister
Keith Pfister has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8563549Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.Type: GrantFiled: May 14, 2012Date of Patent: October 22, 2013Assignee: Novartis AGInventors: Matthew Burger, Zhi-Jie Ni, Sabina Pecchi, Gordana Ataliah, Sarah Bartulis, Kelly Frazier, Aaron Smith, Joelle Verhagen, Yanchen Zhang, Allan Wagman, Simon Ng, Keith Pfister, Daniel J. Poon, Alicia Louie, Teresa Pick, Paul Barsanti, Edwin Iwanowicz, Wendy Fantl, Thomas Hendrickson, Mark Knapp, Hanne Meritt, Charles Voliva, Marion Wiesmann, Xiahua Xin
-
Publication number: 20120225861Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.Type: ApplicationFiled: April 23, 2012Publication date: September 6, 2012Inventors: James C. Sutton, Marion Wiesmann, Weibo Wang, Mika Lindvall, Jiong Lan, Savithri Ramurthy, Anu Sharma, Elizabeth J. Mieuli, Liana M Klivansky, William Lenahan, Susan Kaufman, Hong Yang, Simon C. Ng, Keith Pfister, Allan S. Wagman, Victoria Sung, Martin Sendzik
-
Publication number: 20120225859Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: NOVARTIS AGInventors: Matthew BURGER, Zhi-Jie NI, Sabina PECCHI, Gordana ATALLAH, Sarah BARTULIS, Kelly FRAZIER, Aaron SMITH, Joelle VERHAGEN, Yanchen ZHANG, Allan WAGMAN, Simon NG, Keith PFISTER, Daniel POON, Alicia LOUIE, Teresa PICK, Paul BARSANTI, Edwin IWANOWICZ, Wendy FANTL, Thomas HENDRICKSON, Mark KNAPP, Hanne MERRITT, Charles VOLIVA, Marion WIESMANN, Xiaohua XIN
-
Patent number: 8217035Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.Type: GrantFiled: January 22, 2007Date of Patent: July 10, 2012Assignee: Novartis AGInventors: Matthew Burger, Zhi-Jie Ni, Sabina Pecchi, Gordana Atallah, Sarah Bartulis, Kelly Frazier, Aaron Smith, Joelle Verhagen, Yanchen Zhang, Allan Wagman, Simon Ng, Keith Pfister, Daniel Poon, Alicia Louie, Teresa Pick, Paul Barsanti, Edwin Iwanowicz, Wendy Fantl, Thomas Hendrickson, Mark Knapp, Hanne Merritt, Charles Voliva, Marion Wiesmann, Xiaohua Xin
-
Publication number: 20100280006Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.Type: ApplicationFiled: May 8, 2009Publication date: November 4, 2010Inventors: James C. Sutton, Marion Wiesmann, Weibo Wang, Mika Lindvall, Jiong Lan, Savithri Ramurthy, Anu Sharma, Elizabeth J. Mieuli, Liana M. Klivansky, William Lenahan, Susan Kaufman, Hong Yang, Simon C. Ng, Keith Pfister, Allan S. Wagman, Victoria Sung, Martin Sendzik
-
Publication number: 20100249126Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.Type: ApplicationFiled: January 22, 2007Publication date: September 30, 2010Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Matthew Burger, Zhi-Jie Ni, Sabina Pecchi, Gordana Atallah, Sarah Bartulis, Kelly Frazier, Aaron Smith, Joelle Verhagen, Yanchen Zhang, Allan Wagman, Simon Ng, Keith Pfister, Daniel J. Poon, Alicia Louie, Teresa Pick, Paul Barsanti, Edwin Iwanowicz, Wendy Fantl, Thomas Hendrickson, Mark Knapp, Hanne Meritt, Charles Voliva, Marion Wiesmann, Xiahua Xin
-
Patent number: 7553854Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.Type: GrantFiled: April 18, 2007Date of Patent: June 30, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: James C Sutton, Marion Wiesmann, Weibo Wang, Mika Lindvall, Jiong Lan, Savithri Ramurthy, Anu Sharma, Elizabeth J. Mieuli, Liana M. Klivansky, William Lenahan, Susan Kaufman, Hong Yang, Simon C. Ng, Keith Pfister, Allan S. Wagman, Victoria Sung, Martin Sendzik
-
Publication number: 20080045528Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.Type: ApplicationFiled: April 18, 2007Publication date: February 21, 2008Inventors: James Sutton, Marion Wiesmann, Weibo Wang, Mika Lindvall, Jiong Lan, Savithri Ramurthy, Anu Sharma, Elizabeth Mieuli, Liana Klivansky, William Lenahan, Susan Kaufman, Hong Yang, Simon Ng, Keith Pfister, Allan Wagman, Victoria Sung, Martin Sendzik
-
Publication number: 20070244197Abstract: Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.Type: ApplicationFiled: May 3, 2006Publication date: October 18, 2007Applicant: University of WashingtonInventors: Niels Andersen, Jason Bowman, Alice Erwin, Eric Harwood, Toni Kline, Khisimuzi Mdluli, Simon Ng, Keith Pfister, Ribhi Shawar, Allan Wagman, Asha Yabannavar
-
Publication number: 20070244109Abstract: New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.Type: ApplicationFiled: June 12, 2007Publication date: October 18, 2007Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Manoj Desai, Simon Ng, Zhi-Jie Ni, Keith Pfister, Savithri Ramurthy, Sharadha Subramanian, Allan Wagman
-
Publication number: 20060089369Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.Type: ApplicationFiled: September 6, 2005Publication date: April 27, 2006Applicant: Chiron CorporationInventors: John Nuss, Stephen Harrison, David Ring, Rustum Boyce, Kirk Johnson, Keith Pfister, Savithri Ramurthy, Lynn Seely, Allan Wagman, Manoj Desai, Barry Levine
-
Publication number: 20050203101Abstract: Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.Type: ApplicationFiled: May 5, 2004Publication date: September 15, 2005Inventors: Paul Barsanti, Dirksen Bussiere, Stephen Harrison, Carla Heise, Johanna Jansen, Elisa Jazan, Timothy Machajewski, Christopher McBride, William McCrea, Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith Pfister, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Joel Silver, Allan Wagman, Marion Wiesmann, Kelly Wayman
-
Publication number: 20050069555Abstract: The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.Type: ApplicationFiled: December 29, 2003Publication date: March 31, 2005Inventors: Paul Barsanti, Nathan Brammeier, Anthony Diebes, Liana Lagniton, Simon Ng, Zhi-Jie Ni, Keith Pfister, Casey Philbin, Nicholas Valiante, Allan Wagman, Weibo Wang, Amy Weiner